University College London Featured PhD Programmes
The Francis Crick Institute Featured PhD Programmes
Norwich Research Park Featured PhD Programmes
Imperial College London Featured PhD Programmes
European Molecular Biology Laboratory (Heidelberg) Featured PhD Programmes

The role of metabolic adaptive changes in therapy resistance in Acute myeloid leukaemia (AML)

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  • Full or part time
    Dr P Gallipoli
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

A graduate with an interest in Cancer Biology, with or is expecting at least an upper second class honours degree in biological / biochemistry subject is required for this project involving the study of metabolic adaptive changes in therapy resistance in AML. The project will commence in November 2019 and has funding for 3 years. The student will be based primarily at the Barts Cancer Institute, Barts and the London School of Medicine and Dentistry (SMD), Charterhouse Square in the City of London.

Our buddying multidisciplinary team funded by the recently awarded CRUK Advanced Clinician Scientist Fellowship will focus on the impact of metabolic adaptations on leukaemic stem cell biology and their role in resistance to current therapeutics in acute myeloid leukaemia (AML).

Metabolic rewiring is a known hallmark of cancer and our recent work has highlighted its role in the establishment and maintenance of leukaemia specifically under therapeutic pressure (Gallipoli et al., Blood. 2018 Apr 12;131(15):1639-1653). The group will investigate, using a multidisciplinary approach and multiple models of AML, how changes in metabolism control normal stem cell functions and leukaemic transformation and allow leukaemic cells to withstand therapeutic pressure to exploit these mechanisms to identify therapeutic targets to eradicate cancer stem cells/resistant cells in AML.

The candidate will gain experience in phenotypic characterisation of leukaemia models in vitro and in vivo, mass-spectrometry and ChIP/RNA-sequencing analysis. We enjoy close links with Barts Hospital and have a strong translational focus and the candidate will be joining a project with excellent prospects for developing new therapies and making a significant contribution to our field. This programme will also join the emerging field of cancer metabolism, and its role in cancer biology, thus offering significant opportunity for multidisciplinary training, new discovery and excellent career development.

Funding Notes

The funding for this studentship only covers tuition fees at the home/EU rate. Overseas applicants are welcome to apply, but will be required to fund the difference in tuition fees.

The studentship includes the following funding for 3 years:
- A tax-free annual stipend of £21,000
- Tuition fees at the Home/EU rate*
- Project consumables

Related Subjects

How good is research at Queen Mary University of London in Clinical Medicine?

FTE Category A staff submitted: 144.11

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities


FindAPhD. Copyright 2005-2019
All rights reserved.